Aspirin use in patients with diagnosed diabetes in the United States and China: Nationally representative analysis.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM Diabetes & Vascular Disease Research Pub Date : 2021-10-01 DOI:10.1177/14791641211067416

Xin Wang, Guang Hao, Zuo Chen, Linfeng Zhang, Yuting Kang, Ying Yang, Congyi Zheng, Haoqi Zhou, Lu Chen, Zengwu Wang, Runlin Gao

{"title":"Aspirin use in patients with diagnosed diabetes in the United States and China: Nationally representative analysis.","authors":"Xin Wang, Guang Hao, Zuo Chen, Linfeng Zhang, Yuting Kang, Ying Yang, Congyi Zheng, Haoqi Zhou, Lu Chen, Zengwu Wang, Runlin Gao","doi":"10.1177/14791641211067416","DOIUrl":null,"url":null,"abstract":"Background: The epidemiological data on the use of aspirin in diabetic patients is very limited. The main purpose of this study is to examine the current status of aspirin use in the United States (US) and China in large representative populations.Methods: Data came from the National Health and Nutrition Examination Survey (NHANES) and China Hypertension Survey (CHS), two nationally representative cross-sectional studies.Results: The percentage of aspirin use was 73.8% in US diabetic patients with ASCVD, and the percentage of aspirin use in diabetic patients with high ASCVD risk was marginally higher in men (p = .052), 54.5% in men and 37.1% in women. The percentages of aspirin use in diabetic patients with intermediate and low ASCVD risk were 55.1% and 35.0%, respectively. In China, the percentage of aspirin use in diabetic patients with ASCVD was 53.5%, and were 14.3%, 9.7%, and 3.2% among diabetic patients with high, intermediate, and low ASCVD risk, respectively.Conclusions: In summary, the percentage of aspirin use in primary prevention in US diabetic patients in men was higher than in women, and this percentage for primary and secondary prevention in US patients was higher than that in Chinese patients.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"18 6","pages":"14791641211067416"},"PeriodicalIF":2.8000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/ff/10.1177_14791641211067416.PMC8867494.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Vascular Disease Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14791641211067416","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 3

Abstract

Background: The epidemiological data on the use of aspirin in diabetic patients is very limited. The main purpose of this study is to examine the current status of aspirin use in the United States (US) and China in large representative populations.

Methods: Data came from the National Health and Nutrition Examination Survey (NHANES) and China Hypertension Survey (CHS), two nationally representative cross-sectional studies.

Results: The percentage of aspirin use was 73.8% in US diabetic patients with ASCVD, and the percentage of aspirin use in diabetic patients with high ASCVD risk was marginally higher in men (p = .052), 54.5% in men and 37.1% in women. The percentages of aspirin use in diabetic patients with intermediate and low ASCVD risk were 55.1% and 35.0%, respectively. In China, the percentage of aspirin use in diabetic patients with ASCVD was 53.5%, and were 14.3%, 9.7%, and 3.2% among diabetic patients with high, intermediate, and low ASCVD risk, respectively.

Conclusions: In summary, the percentage of aspirin use in primary prevention in US diabetic patients in men was higher than in women, and this percentage for primary and secondary prevention in US patients was higher than that in Chinese patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美国和中国诊断为糖尿病的患者阿司匹林的使用:全国代表性分析

背景:糖尿病患者使用阿司匹林的流行病学资料非常有限。本研究的主要目的是在美国和中国的大型代表性人群中检查阿司匹林的使用现状。方法:数据来自全国健康与营养调查(NHANES)和中国高血压调查(CHS)，这是两项具有全国代表性的横断面研究。结果:在美国合并ASCVD的糖尿病患者中，阿司匹林的使用比例为73.8%，而在ASCVD高风险的糖尿病患者中，阿司匹林的使用比例男性略高(p = 0.052)，男性为54.5%，女性为37.1%。中度和低ASCVD风险的糖尿病患者使用阿司匹林的比例分别为55.1%和35.0%。在中国，合并ASCVD的糖尿病患者使用阿司匹林的比例为53.5%，高、中、低ASCVD风险的糖尿病患者分别为14.3%、9.7%和3.2%。结论:综上所述，美国男性糖尿病患者一级预防使用阿司匹林的比例高于女性，且美国患者一级和二级预防使用阿司匹林的比例均高于中国患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes & Vascular Disease Research ENDOCRINOLOGY & METABOLISM-PERIPHERAL VASCULAR DISEASE

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. The journal publishes original papers, research letters and reviews. This journal is a member of the Committee on Publication Ethics (COPE)